Kaylyn D. Tousignant

Kaylyn D. Tousignant

Auto-generated profile, based on publicly available information

Kaylyn D. Tousignant

Australian Prostate Cancer Research Centre - Queensland, Institute of Health and Biomedical Innovation, School of Biomedical Sciences, Faculty of Health, Queensland University of Technology (QUT), Princess Alexandra Hospital, Translational Research Institute, Brisbane, Australia

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 June 2020 in Cancer & Metabolism
Verified
Journal Article
Open access
PDF file
KTKaylyn D. Tousignant
Kaylyn D. Tousignant
ARAnja Rockstroh
Anja Rockstroh
BPBerwyck L. J. Poad
Berwyck L. J. Poad
ATAli Talebi
Ali Talebi
RYReuben S. E. Young
Reuben S. E. Young
MSMartin C. Sadowski
Martin C. Sadowski
Background: Metabolic reprograming, non-mutational epigenetic changes, increased cell plasticity, and multidrug tolerance are early hallmarks of therapy resistance in cancer. In this temporary, therapy-tolerant state, cancer cells are highly sensitive to ferroptosis, a form of regulated cell death that is caused by oxidative stress through excess levels of iron-dependent peroxidation of polyunsaturated fatty acids (PUFA). However, mechanisms underpinning therapy-induced ferroptosis hypersensitivity remain to be elucidated. Methods: We used quantitative single-cell imaging of fluorescent metabolic probes, transcriptomics, proteomics, and lipidomics to perform a longitudinal analysis of the adaptive response to androgen receptor-targeted therapies (androgen deprivation and enzalutamide) in prostate cancer (PCa). Results: We discovered that cessation of cell proliferation and a robust reduction in bioenergetic processes were associated with multidrug tolerance and a strong accumulation of lipids. The gain in lipid biomass was fueled by enhanced lipid uptake through cargo non-selective (macropinocytosis, tunneling nanotubes) and cargo-selective mechanisms (lipid transporters), whereas de novo lipid synthesis was strongly reduced. Enzalutamide induced extensive lipid remodeling of all major phospholipid classes at the expense of storage lipids, leading to increased desaturation and acyl chain length of membrane lipids. The rise in membrane PUFA levels enhanced membrane fluidity and lipid peroxidation, causing hypersensitivity to glutathione peroxidase (GPX4) inhibition and ferroptosis. Combination treatments against AR and fatty acid desaturation, lipase activities, or growth medium supplementation with antioxidants or PUFAs altered GPX4 dependence. Conclusions: Our work provides mechanistic insight into processes of lipid metabolism that underpin the acquisition of therapy-induced GPX4 dependence and ferroptosis hypersensitivity to standard of care therapies in PCa. It demonstrates novel strategies to suppress the therapy-tolerant state that may have potential to delay and combat resistance to androgen receptor-targeted therapies, a currently unmet clinical challenge of advanced PCa. Since enhanced GPX4 dependence is an adaptive phenotype shared by several types of cancer in response to different therapies, our work might have universal implications for our understanding of metabolic events that underpin resistance to cancer therapies.

1 May 2019 in Molecular Cancer Research
Verified
Journal Article
Open access
PDF file
KTKaylyn D. Tousignant
Kaylyn D. Tousignant
ARAnja Rockstroh
Anja Rockstroh
AFAtefeh Taherian Fard
Atefeh Taherian Fard
MLMelanie L. Lehman
Melanie L. Lehman
CWChenwei Wang
Chenwei Wang
MSMartin C. Sadowski
Martin C. Sadowski
De novo lipogenesis is a well-described androgen receptor (AR)–regulated metabolic pathway that supports prostate cancer tumor growth by providing fuel, membrane material, and steroid hormone precursor. In contrast, our current understanding of lipid supply from uptake of exogenous lipids and its regulation by AR is limited, and exogenous lipids may play a much more significant role in prostate cancer and disease progression than previously thought. By applying advanced automated quantitative fluorescence microscopy, we provide the most comprehensive functional analysis of lipid uptake in cancer cells to date and demonstrate that treatment of AR-positive prostate cancer cell lines with androgens results in significantly increased cellular uptake of fatty acids, cholesterol, and low-density lipoprotein particles. Consistent with a direct, regulatory role of AR in this process, androgen-enhanced lipid uptake can be blocked by the AR-antagonist enzalutamide, but is independent of proliferation and cell-cycle progression. This work for the first time comprehensively delineates the lipid transporter landscape in prostate cancer cell lines and patient samples by analysis of transcriptomics and proteomics data, including the plasma membrane proteome. We show that androgen exposure or deprivation regulates the expression of multiple lipid transporters in prostate cancer cell lines and tumor xenografts and that mRNA and protein expression of lipid transporters is enhanced in bone metastatic disease when compared with primary, localized prostate cancer. Our findings provide a strong rationale to investigate lipid uptake as a therapeutic cotarget in the fight against advanced prostate cancer in combination with inhibitors of lipogenesis to delay disease progression and metastasis.Implications: Prostate cancer exhibits metabolic plasticity in acquiring lipids from uptake and lipogenesis at different disease stages, indicating potential therapeutic benefit by cotargeting lipid supply.

23 February 2018 in Journal of Natural Products
Verified
Journal Article
Closed access
FEFolake A. Egbewande
Folake A. Egbewande
MSMartin C. Sadowski
Martin C. Sadowski
CLClaire Levrier
Claire Levrier
KTKaylyn D. Tousignant
Kaylyn D. Tousignant
JWJonathan White
Jonathan White
RDRohan Davis
Rohan Davis

3 November 2021 in bioRxiv
Verified
Preprint
Open access
RYReuben S. E. Young
Reuben S. E. Young
ABAndrew Bowman
Andrew Bowman
KTKaylyn D. Tousignant
Kaylyn D. Tousignant
BPBerwyck L. J. Poad
Berwyck L. J. Poad
JGJenni Gunter
Jenni Gunter
SBStephen J. Blanksby
Stephen J. Blanksby
1.0 Summary: Cellular energy and biomass demands of cancer drive a complex dynamic between uptake of extracellular fatty acids (FA) and de novo synthesis. Given that oxidation of de novo synthesised FAs for energy would result in net-energy loss, there is an implication that FAs from these two sources must have distinct metabolic fates - however hitherto FAs were considered part of a common pool. To probe FA metabolic partitioning, cancer cells were supplemented with stable-isotope labelled FAs. Structural analysis of the resulting glycerophospholipids revealed that labelled FAs from uptake were largely incorporated to canonical ( sn -)positions on the glycerol backbone. Surprisingly, labelled FA uptake disrupted canonical isomer patterns of the unlabelled lipidome and induced repartitioning of n -3 and n -6 polyunsaturated-FAs into glycerophospholipid classes. These structural changes evidence differences in the metabolic fate of FAs derived from uptake or de novo sources and demonstrate unique signalling and remodelling behaviours usually hidden to conventional lipidomics. Highlights: Lipid isomers reveal discrete metabolic compartmentalisation in cancer FAs derived from uptake and de novo synthesis have different metabolic fates Stearate uptake signals for PUFA ( n -3 and n -6) repartitioning between lipid classes sn -positional isomers are a marker for aberrant lipid metabolism